Market Research Blog

Mitochondria present in a human cell is responsible for converting food into energy in body. Mutations of mitochondrial DNA can lead to several illnesses that cause poor growth, muscle weakness, learning disabilities, increased risk of infection, respiratory problem and many more.

Mitochondrial disorders are rare and chronic affecting several body parts like nerves, heart, kidney, liver and pancreas. Some disorders caused due to excess mitochondrial DNA mutation are Leber’s hereditary optic neuropathy, Leigh syndrome, mitochondrial myopathy, mitochondrial DNA depletion syndrome and others.

According to the National Institute of Health (NIH), mitochondrial disease is a type of genetic disease with a minimum prevalence of greater than 1 in 5000 people across the globe.Covid-19 has led to lockdown in several countries delaying manufacturing activities in mitochondrial DNA market.

Ask for brochure of Market @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-12580

There has been observed supply chain disruption due to restrictions laid on trading across borders by various countries. The significant decline in hospital visits and the treatment-seeking rate will impact mitochondrial DNA market. Leading biopharmaceuticals are inclined towards developing coronavirus cure, delaying other clinical trials impact the growth rate of mitochondrial DNA market.

Mitochondrial DNA Market: Drivers and Restraints

The rise in the prevalence of mitochondrial disorders increases the demand for mitochondrial DNA market. Clinical stage development biopharmaceuticals attract investments from private players leading to an expansion of mitochondrial DNA market.

For instance, In June 2018, Stealth Biotherapeutics Corp. announced $100 million funds being raised from investors to develop and commercialize Elamipretide drug used as therapeutic for mitochondrial myopathy which is caused due to mutations in mitochondrial DNA.

Advancement in technology and research and development activities is expected to fuel mitochondrial DNA market growth. Lack of awareness about therapeutic options available for mitochondrial dysfunction is expected to hinder mitochondrial DNA market growth. The stringent regulatory requirement for drug approval is a challenging factor for mitochondrial DNA market growth.

Mitochondrial DNA Market: Overview

NSAIDs is expected to hold a major revenue share of mitochondrial DNA market during the forecast period. Therapeutic application is expected to dominate the mitochondrial DNA market during the forecast period with an increasing prevalence of mitochondrial disorders.

Diagnostic application in mitochondrial DNA market holds a significant share due to its ability to help detect cancer. Oral drugs are most common for mitochondrial DNA market. Whereas, hospital pharmacies is the largest distribution channel for mitochondrial DNA market. Increased adoption of e-commerce is will increase the demand for online pharmacies in mitochondrial DNA market.

Mitochondrial DNA Market: Region-wise Outlook

North America will continue to dominate the mitochondrial DNA market in the coming decade with a high rate of prevalence of mitochondrial disorders. The high rate of approvals and commercialization of pharmaceutical drugs increases the demand for mitochondrial DNA market in North America.

Europe is the second leading region in the mitochondrial DNA market with increased investments towards drug development and advanced technology. Asia-pacific is lucrative market with a higher growth rate in the mitochondrial DNA market during the forecast period with a large patient population in the region and increasing healthcare expenditure.

The Middle East and Africa are expected to observe the least growth in mitochondrial DNA market due to poor healthcare infrastructure and economic conditions in the region.

Mitochondrial DNA Market: Key Market Participants

Major players in mitochondrial DNA market include

• Pfizer Inc.
• Novartis AG
• Takeda Pharmaceuticals
• Amgen Inc.
• NeuroVive Pharmaceutical AB
• Entogene AG
• Stealth Biotherapeutics
• Ixchel Pharma
• Reata Pharmaceuticals
• Khondrion BV
• Alkeus Pharmaceuticals
• Intercept Pharmaceutics

The research report on mitochondrial DNA market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on mitochondrial DNA market provides analysis and information according to market segments such as drug class, route of administration, application, and region.

The report covers exhaust analysis on:

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Regional analysis includes:

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Europe (Germany, Italy, France, U.K, Spain, Russia)
• East Asia (China, Japan, South Korea)
• South Asia (India, ASEAN)
• Oceania (Australia, New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

• Detailed overview of parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-12580

Mitochondrial DNA Market: Segmentation

drug type:

• Anti-inflammatory Biologics
• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids

application:

• Therapeutic
• Research and development
• Diagnostic

route of administration:

• Oral
• Intravenous

distribution channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Sudden loss in kidney function and increasing serum creatinine level without loss of urine are observed in ICU-acquired acute kidney. It is observed in people who have been admitted in the ICU for a particular treatment.

The ICU-acquired acute kidney treatment market is segmented based on type, therapy type and regions. On the basis on type, the market is divided into pre-renal, intrinsic-renal and post-renal. Based on therapy type, the market is segmented into intermittent hemodialysis, continuous renal replacement therapy and sustained low-efficiency dialysis.

With the COVID-19 breakout in December 2019, the disease has affected more than 200 countries. Therefore, it is important to take this into consideration while addressing ICU-acquired acute kidney treatment market.

Request for Report brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-12579

The disease may have led to temporary lag in the ICU-acquired acute kidney treatment market, but in the long run the ICU-acquired acute kidney treatment market is expected to pace up and flourish at a significant rate during the forecast period 2020-2030.

ICU-acquired Acute Kidney Treatment Market: Drivers and Restraints

Increasing prevalence of lifestyle-related diseases such as obesity & diabetes and rising incidence of renal failure cases are the major factors that are expected to drive the growth of the ICU-acquired acute treatment market.

Moreover, the rising geriatric population, increasing health expenditure among the population, increasing initiatives by the government to manage chronic kidney diseases and technological advancement in the healthcare sector may also boost the growth of the ICU-acquired acute treatment market.

However, stringent rules by various health authority for product approvals and low awareness regarding treatment in developing and underdeveloped countries may hinder the growth of the ICU-acquired acute kidney treatment market.

ICU-acquired Acute Kidney Treatment Market: Overview

On the basis of treatment type,the ICU-acquired acute kidney treatment market is segmented into pre-renal, intrinsic-renal and post renal. In this segment, intrinsic-renal is expected to be the major contributor of revenue and will lead to the growth of ICU-acquired acute kidney treatment market.

On the basis of therapy type, the ICU-acquired acute kidney treatment market is segmented into intermittent hemodialysis, continuous renal replacement therapy and sustained low-efficiency dialysis. In this segment, intermittent hemodialysis may continue to grow as it is highly effective in achieving solute removal.

ICU-acquired Acute Kidney Treatment Market: Regional-Wise

The global ICU-acquired acute kidney treatment market is segmented into 5 regions i.e. North America, Latin America, Europe, Asia-Pacific and Middle East &Africa.

North America is expected to dominate the ICU-acquired acute kidney treatment market in terms of revenue during the forecast period due to growing no. of research activities and availability of drugs for treatment of the disease in this region.

Europe is expected to be 2^nd highest contributor in terms of revenue in the ICU-acquired acute kidney treatment market. On the other hand, Asia Pacific is expected to experience fastest growth in the ICU-acquired acute kidney treatment market as a result of rising no. of kidney disorders, increasing geriatric population and higher investment for better healthcare facilities in countries in this region.

The growth of the ICU-acquired acute kidney treatment market is expected to be limited in the Middle East & Africa due to slow economic growth and limited development in healthcare sector.

ICU-acquired Acute Kidney Treatment Market: Key players

Some of the players identified in the ICU-acquired acute kidney treatment market include:

• Quark Pharmaceuticals Inc.
• Fresenius medical care AG & Co. KGaA
• B. Braun Melsungeb AG
• Baxter international, Inc.
• Angion Biomedical Corp
• LG chem
• Asahi Kasei medical Co. Ltd

The report covers exhaustive analysis on:

• ICU-acquired Acute Kidney Treatment Market Segments
• ICU-acquired Acute Kidney Treatment Market Dynamics
• Historical Actual Market Size, 2013 – 2017
• ICU-acquired Acute Kidney Treatment Market Size & Forecast 2018 to 2024
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Market Drivers and Restraints

Regional analysis includes

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Report Highlights:

• Shifting Industry dynamics
• In-depth market segmentation
• Historical, current and projected industry size recent industry trends
• Key Competition landscape
• Strategies for key players and product offerings
• Potential and niche segments/regions exhibiting promising growth
• A neutral perspective towards market performance

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-12579

ICU-acquired Acute Kidney Treatment Market: Segmentation

The globalICU-acquired acute kidney treatment markethas been segmented on the basis oftreatment type, application and end user.

treatment type:

• Pre-renal
• Intrinsic-renal
• Post-renal

therapy type:

• Continuous renal replacement therapy
• Intermittent hemodialysis
• Sustained low-efficiency dialysis

region?:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Non-surgical fat reduction is a minimally invasive treatment of body fat reduction. Non-surgical fat reduction is conducted through various technologies including heat, cooling, medication and injectable. Non-surgical fat reduction is performed with variety of devices, including radio frequency, infrared light, ultrasound, and injectable medication. The global non-surgical fat reduction market is expected to reach a value of US$ 220.0 Mn by the end of 2022, according to a latest research by Future Market Insights (FMI). The report on the non-surgical fat reduction market further projects significant growth potential with average year-on-year growth rate of 5.1% through 2022.

Obesity leads to serious health problems including heart disease, high blood pressure, diabetes, and cancers in certain cases. Excess deposition of body fat triggers insulin production, which lead to diabetes. According to a study conducted by Harvard, the risk of diabetes is 20 times more in obese population. This also increases the risk of high blood pressure, gallstones and stroke. The growing number of obese population is seeking for cost-effective, less painful non-surgical fat reduction procedures, which can be performed at outpatient centres or beauty clinics. Some of the most popular procedures among non-surgical fat reduction are injection lipolysis, cryolipolysis, laser lipolysis, and radiofrequency lipolysis.

Click the link to get a free Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5321

The non-surgical fat reduction market is predominated by few companies that are offering their approved products to the end users. These companies are competing in the non-surgical fat reduction market through product differentiation strategy. The leading players operating in the market have varied range of products, which operate on different technologies. Non-surgical fat reduction is gaining popularity among teen-age groups. According to the American Society of Plastic Surgeons (ASPS), approximately 229,000 cosmetic procedures were conducted on teen-aged patients (age 13 to 19) in 2017. The prime reason behind the increased number of plastic surgeries among teen-age group is social media-obsessed culture, where teenagers opt for various type of plastic surgery. The increasing number of teen-age population across beauty clinics is likely to boost the growth of Non-surgical fat reduction market.

Non-surgical fat reduction is gaining popularity among women who have undergone C-section during their pregnancy. This patient population is seeking for body-contouring treatments for their post-pregnancy marks. Non-surgical fat reduction is a cost-effective solution for body-contouring women. Non-surgical fat reduction techniques available in the market are also targeting population that are looking for temporary fat reduction solution. In order to cater the demand, Syneron Medical Ltd (UltraShape) & Valeant Pharmaceuticals International, Inc. (Liposonix) are offering FDA approved products for ultrasound fat reduction treatment. The devices offered by the companies use focused ultrasonic waves to break the fat while leaving surrounding tissues unharmed. Non-surgical fat reduction with laser-based technology is adopted by patient looking for fat reduction in particular areas such as hips, waist and thighs.

Most of the surgeons does not recommend laser-based surgery for pregnant mothers, or women trying to conceive or for people with pacemakers. Based on the product type, the laser-based devices segment is expected to account a high share in the global non-surgical fat reduction market in terms of value throughout the forecast period. Moreover, this segment is projected to register a CAGR of 5.6% through 2022.

FMI has segmented the global non-surgical fat reduction market based on product type, end users, & regions. In terms of revenue, the beauty clinics end-user segment holds substantial share in the non-surgical fat reduction market and is expected to gain momentum over the forecast period due to increasing awareness regarding cost-effective non-surgical fat reduction procedures.

Examples of some of the companies profiled in the report are Cutera Inc., Syneron Medical Ltd., Lutronic Corporation, Fotona d.d., Cynosure, Inc., Solta Medical Inc., Lynton Lasers Ltd., Alma Lasers, Ltd., Venus Concept Canada Corp., EL.En. S.p.A., and Sciton, Inc.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-5321

Additional Questions Answered

Some of the additional questions addressed in the report for Non-Surgical Fat Reduction market-

• What is role of regulatory authority and plastic surgery service providers in market?
• What is the revenue potential of Non-Surgical Fat Reduction over conventional invasive fat reduction procedures?
• How Non-Surgical Fat Reduction market is gaining momentum in Asia region?
• Who are the key competitors and what are their portfolios in Non-Surgical Fat Reduction market?
• What is the price point for Non-Surgical Fat Reduction devices in developed countries?
• What is the current level competition in the Non-Surgical Fat Reduction market?

As the prevalence of lung cancer, melanoma, and renal cell carcinoma continues to soar worldwide, the adoption of PD-L1 biomarker testing is expected to grow at a healthy pace in the years to come, says Future Market Insights (FMI) in its new market study. Moreover, the report forecasts that the global PD-L1 biomarker testing market will grow in value at a stellar CAGR of 13.1% between 2020 and 2030.

The report opines that the outbreak of COVID-19 is likely to create short-term fluctuations on the supply side due to pandemic-related issues such as workforce shortages and disruptions of delivery networks. Similarly, a steep decline in the number of tests has been observed during the pandemic, and this is expected to further decelerate the demand for PD-L1 biomarker testing.

The report primarily attributes the growth of the market to the increasing incidence of cancers, especially lung and skin, coupled with the development of advanced diagnostic kits and assays.

Click the link to get a free Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5897

Likewise, rising awareness regarding the availability of testing methodology such as immunohistochemistry-based assays and Enzyme-linked Immunoassay (ELISA) based detection will continue to impel the adoption of PD-L1 biomarkers in the forthcoming years.

Key Takeaways

• The global PD-L1 biomarkers testing market is expected to surge past valuation of US$ 2.05 Bn by the end of the forecast period.
• PD-L1 SP142 assay kits will remain the most popular products among end-users, capturing nearly half of the market value, owing to high efficiency in detecting cancer tumors.
• Non-small cell lung cancer and melanoma are cumulatively expected to hold more than 50% of the total market value on the back of the soaring prevalence of these diseases.
• By end-use, PD-lL1 biomarker testing finds the majority of applications in hospitals, which is expected to account for over 60% of market value.
• North America will spearhead the regional landscape through the forecast period, accounting for more than 50% of the global market value.
• Europe is poised to remain the second most lucrative region, holding nearly 1/3rd of market value.

“Market players are directing their efforts towards improving the accessibility of these products and are marking them cost-effective to ensure wide-scale adoption,” remarks FMI analyst.

COVID-19 Impact on PD-L1 Biomarker Testing Market

The COVID-19 pandemic has created disruptions across the healthcare technology landscape and has resulted in a shifting preference among manufacturers towards essential technologies and treatments. Furthermore, although PD-L1 biomarker testing is used to test severe diseases such as cancer, a reduced number of screenings is adversely impacting the demand for testing.

For instance, according to trends observed by Cancer Research Network, screening rates of melanoma plummeted by approximately 50% in the UK in the past few months. Likewise, in the US, the number of tests conducted to detect non-small cell lung cancer fell by 30% in March as compared to February. As patients reschedule or skip regular screenings, this is creating a downtrend in demand for PL-D1 biomarker testing.

However, considering the severity of these diseases, the need for testing will swiftly arise in the future, ensuring that the market’s growth trajectory remains intact.

Who is Winning?

Key players operating in the market are focusing on enhancing existing product designs and developing novel products with increased accuracy. Moreover, traditional growth strategies such as acquisitions and mergers have been identified as strategies adopted by players to strengthen their foothold in the competitive landscape.

• In January 2019, Abcam Plc acquired Calico Biolabs with an objective to expand its custom monoclonal production service capabilities.
• In December 2018, NeoGenomics, Inc. acquired Genoptix, Inc. to improve its oncology diagnostic services.

FMI’s report includes profiles of some of the most prominent names in the market including F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., NeoGenomics Laboratories, Inc, HalioDx and Abcam plc. among others.

For Complete TOC @ https://www.futuremarketinsights.com/toc/rep-gb-5897

To Know More About PD-L1 Biomarkers Market

A new market research report published by Future Market Insights (FMI) on the global PD-L1 biomarkers market offers an executive-level blueprint of the market. It offers insights into demand trends and provides analysis of opportunities over the forecast period, 2020-2030. The report examines the market through four different segments – product, indication, end-use, and region. The report also provides extensive assessment of pricing by different key market dynamics, life cycle analysis, and technologies that are being deployed in the supply and product adoption across several end-use industries.

ESOMAR-certified consulting firm Future Market Insights’ report, projects a healthy growth, for optical coherence tomography (OCT) market. As per the report, the market is forecast to reach a valuation of US$ 1349.09 Mn over the forecast period of 2021 and 2031.

Growing application of OCT in ophthalmology across China, the U.K., Germany and Japan will bolster the demand of optical coherence tomography across the globe.

As per the FMI’s analysis, the optical coherence tomography market across Japan and China is anticipated to expand at over 9.8% and 4.6%, respectively in 2021. Growing prevalence of eye related disorders such as diabetic retinopathy, glaucoma and others will improve the adoption of OCT imaging systems.

Development of advanced OCT imaging systems coupled with increasing government & private organizations initiatives for eye care programs across the globe are propelling the adoption of OCT imaging systems.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3362

Growing awareness and increasing innovation for the advanced OCT devices for the treatment of skin cancer and eye diseases have urged the manufacturers to incorporate real-time data for better outcomes, expanding their existing product ranges.

Based on the aforementioned factors, the OCT market is slated to expand at a robust pace of over 6.7% CAGR during the assessment period of 2021 and 2031.

Key Takeaways from FMI’s Optical Coherence Tomography Market Study

• Hospitals are anticipated emerge as primary end users of optical coherence tomography market, accounting for leading market share
• Preference for spectral domain-OCT will be higher as compared to swept source-OCT over the forecast period
• Increasing application of OCT in ophthalmology is expected to drive sales through 2031
• Germany and the U.K. will lead the Europe’s optical coherence tomography market on the back of rising cases of eye disorders across the region
• Japan is anticipated to emerge as a lucrative market backed by the rising development of advanced OCT imaging systems within healthcare sector
• China is anticipated to lead the East Asia market during the forecast period, accounting for over 4.6% market sales
• The U.S. is estimated to be the largest market for optical coherence tomography market attributed to be growing prevalence of eye related disorders

“Key players are increasing research and development activities for the development of advanced OCT imaging system for the early detection & treatment of eye-related disorders. This, in turn, is likely to omprovegrowth opportunities for the market players over the coming years,” says the FMI analyst. 

Optical Coherence Tomography Market Competitive Landscape

Future Market Insights, in its updated report, have profiled prominent players operating in optical coherence tomography market which include Leica Microsystems, Optovue Inc., Carl Zeiss Meditec AG, Santec Corporation, Heidelberg Engineering GmbH, Optopol Technology SP Z.O.O., Topcon Corporation, Michelson Diagnostic Ltd., Tomophase Inc., Moptim Imaging Technique, NIDEK Co. Ltd., and Sonostar Technologies Co. Ltd among others.

Optical coherence tomography systems manufacturers are actively focusing on expanding their product portfolios to improve their revenue generation.

Incorporation of advanced technology combined with the upgradation of its existing range of products is also one of the core strategies of market players to maintain their position in the industry.

The global optical coherence tomography market is dominated by top tier-1 market players that include Leica Microsystem (Sub. Danaher), Optovue Inc., and Zeiss Group (Carl Zeiss Meditec AG).

Targeted mergers and collaborations with top distribution channel partners is anticipated to be the key strategy to maintain their top position in the industry. Around 20% to 25% of global market revenue is contributed by the tier-1 players over the forecast period.

New product launches with the expansion of their existing product range is one of the common market strategy for the key players. For instance:

In March 2021, Premier Medical Imaging AI Inc., a medical technology company focusing to transform cancer surgery with ultra-high resolution, announced the 510 (k) clearance for its Perimeter’s Optical Coherence Tomography imaging system (v2.1) from the U.S. Food & Drug Administration (FDA), designed to examine tissue microstructures during surgical procedures.

In January 2021, Notal Vision announced the launch of its first ‘US Home-Based’ optical coherence tomography platform which was patient self-operated.

To gain more insights into the market with a detailed table of content and figures, click here:  https://www.futuremarketinsights.com/toc/rep-gb-3362

More Insights on the Global Optical Coherence Tomography Market

Future Market Insights, in its latest report, offers an incisive coverage on the global optical coherence tomography market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is classified on the basis of product type (spectral domain-OCT, swept source-OCT, and others), application type (ophthalmology, dermatology, cardiovascular, dental, and others), and end user (hospitals, ophthalmology clinics, dermatology clinics, dental clinics, ambulatory surgical centers, and others) across seven major regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Femtech is a term used for female technology which involves the use of digital health tools including software, diagnostics, products, and services that are targeted at women’s health. According to a recent Future Market Insights (FMI) report, the global femtech market is estimated to hit a valuation of US$ 948.1 Mn in 2021, with a market CAGR of 15.0% during the forecast period (2021-2031).

Market demand is set to rise at a steady pace throughout the forecast period, majorly favoured by investments outside the boundaries of healthcare towards a branched approach involving domains such as workplace regulations, financial equity, and state legislation.

The primary factor supporting the femtech market to positive expansion in terms of growth and stability is the advent of digitalization and artificial intelligence. Technological advancements such as cloud-based informatics allow personalized solutions, driven by consumer input. This has given rise to affordable and accessible analysis in terms of personal health monitoring and diagnosis.

Click the link to get a free Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11761

Key market players have pushed for innovation and accessibility into customized digital solutions. This also includes the introduction of hands-free wearables which are assistive with the regular, day-to-day life of women across the globe.

Additionally, leading product developers in the femtech market work through commercial partners such as department stores, big-box retailers, hospitals, clinics, insurance companies, pharmacies and drugstores, private medical practices and e-commerce platforms to expand product sales prospects.

Key Takeaways from Femtech Market Study

• Menstrual health applications will drive market growth holding around a third of the market, supported by growing purchases from the working women demographic.
• Diagnostic services are projected to cover about 45% of the global market by 2031. This is aided by the growing accessibility of digital health services
• The U.S. holds a dominant share, valuing at over US$ 357.1 Mn by the end of 2021, supported by the presence of leading players and higher consumer acceptance.
• The U.K. and Germany dominate the Europe market, cumulatively accounting for more than 25% of the regional revenue.
• China is a leading market in East Asia, and is forecast to account for more than 50% of the regional value share owing to a vast consumer base.

“The advent of technological improvements in healthcare in the form of devices, applications, services, and products has increased the rate of diagnosis of reproductive disorders in terms of time management and treatments for women. This will aid growth through the upcoming decade,” says the FMI Analyst

Who is Winning?

Some of the leading companies operating in the femtech market are focusing on collaborations with leading institutions for increasing awareness among the population about the adoption of digital health services.

Collaborations with key pharmaceutical companies to launch customized products and services for the growing consumer base has led key players to retain their position in the market while expanding their product portfolio.

• Research collaboration in monitoring fetal heart rates through wearable ECG chips by between Bloomlife and Imec in 2019 has expectantly given rise to superior monitoring capabilities in maternity care.
• Femtech companies have integrated applications for tracking fertility and offer services such as in-vitro fertilization. Additionally, they also offer medical treatments and products such as wearables and hands-free devices.

Key market players covered by FMI include Clue, Aparito Limited, Bloomlife, Bonzun Health Information AB, Elvie, Ava Science Inc., Grace Health, iBreve, LactApp, Natural Cycles Nordic AB, Hera Med Ltd., Niramai Health, NURX Inc., SteadySense GmbH, Pregnolia AG, Willow, WOOM and B-wom.

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-11761

Want More Insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global femtech market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the femtech market based on service (diagnostics, monitoring, therapeutic), application (general health and wellness, maternity care, menstrual health, pelvic and uterine healthcare, cancer and chronic disease), and end-user (direct-to-consumer, hospitals, surgical centres, fertility clinics, diagnostics centres) across seven major regions.